Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Forge Therapeutics Achieves CARB-X Milestone | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Forge Therapeutics Achieves CARB-X Milestone

Is now eligible to receive as much as $4 million in additional support to advance novel IV/Oral LpxC antibiotic

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Forge Therapeutics, Inc., a biotechnology company developing medicines targeting metalloenzymes, has achieved technical milestones and received notice from CARB-X to proceed with the next stage of product funding for its novel IV/Oral LpxC antibiotic to treat urinary tract infections. 

In March 2017, CARB-X selected Forge as one of the first recipients of a cost-sharing award to advance promising antibacterial candidates through the early stages of development. To date, Forge has earned $4.8 million over 15 months from CARB-X and is now eligible to receive as much as $4 million in additional support.

“CARB-X funds the best science and most promising research projects around the world to address drug resistance and superbug infections,” said Kevin Outterson, executive director of CARB-X. “Our diverse Powered by CARB-X pipeline, which includes Forge’s LpxC antibiotic, continues to expand with new mechanisms of action, new treatment modalities and increased funding. Our milestone-based funding is designed to reinforce success with early-stage research projects. Congratulations to Forge.”

“The fight against multi-drug resistant bacteria continues to escalate as antibiotic resistance is steadily rising. Together with our partners from CARB-X and Evotec AG, we are at the forefront of this fight, strategically equipped to drive innovation and create life-saving antibiotics,” said Zachary A. Zimmerman, Ph.D., chief executive officer of Forge. “With achievement of this technical milestone, Forge remains well-suited to advance our novel Gram-negative antibiotic to the clinic.” 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics